You are here

Home » Library » Topic Index » HIV Care Continuum » Step 5: Effective Drug Treatment of HIV

Step 5: Effective Drug Treatment of HIV

See also Antiretroviral Therapy, Adherence, and Initiating Treatment

Articles: 8

  • Immediate ART Initiation: Guide for Clinicians

    Susa Coffey's picture

    February 14, 2019

    Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment...

  • AETCs at the 2018 Ryan White Conference

    Judy Collins's picture

    November 26, 2018

    The AETC Program was well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center exhibited an array of AETC Program developed resources and promotional items.  

    TitleSession IDTypePresenters/ PanelistsDate/time...

  • Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

    Jennifer Cocohoba's picture

    April 11, 2018

    Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...

  • Ibalizumab Approved for Persons with Multidrug Resistant HIV

    Susa Coffey's picture

    April 11, 2018

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Laura Cheever's picture

    August 31, 2017

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Susa Coffey's picture

    April 17, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    Jennifer Cocohoba's picture

    April 12, 2016

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    Susa Coffey's picture

    March 18, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...